Browse studies
Find your next paid study
5 recruiting studies matching your filters
Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
Prurigo Nodularis (PN)
Estimated
~$10 – $8,750
Beijing InnoCare Pharma Tech Co., Ltd.NCT07236099
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outc…
Prurigo Nodularis
Estimated
~$10 – $1,125
Galderma R&DNCT06988618
Phase 2
Evaluating the Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients: A 24-Week Study
The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).
Prurigo Nodularis (PN)
Estimated
~$10 – $6,250
University of Maryland, BaltimoreNCT07620561
Phase 3
A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks. * Treatmen…
Prurigo Nodularis
Estimated
~$10 – $7,500
SanofiNCT06293053
Phase 4
A 24 Week, Open-Label Study to Evaluate the Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Prurigo Nodularis
A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
Prurigo Nodularis
Estimated
~$10 – $7,500
Psoriasis Treatment Center of Central New JerseyNCT06773403